We are live on ! Find out more
RGNX icon

Regenxbio

159 hedge funds and large institutions have $610M invested in Regenxbio in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 62 increasing their positions, 51 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $4.47M | Put options by funds: $2.06M

22% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 51

1.14% less ownership

Funds ownership: 85.4%84.26% (-1.1%)

5% less funds holding

Funds holding: 167159 (-8)

18% less capital invested

Capital invested by funds: $742M → $610M (-$132M)

32% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 25

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
159
Holders Change
-8
Holders Change %
-4.79%
% of All Funds
2.52%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
17
Increased
62
Reduced
51
Closed
25
Calls
$4.47M
Puts
$2.06M
Net Calls
+$2.41M
Net Calls Change
-$136K
Name Holding Trade Value Shares
Change
Change in
Stake
AI
26
ArchPoint Investors
Florida
$3.69M
American Century Companies
27
American Century Companies
Missouri
$3.58M -$865K -47,749 -18%
PAM
28
Panagora Asset Management
Massachusetts
$3.57M +$323K +17,805 +9%
Mirae Asset Global Investments
29
Mirae Asset Global Investments
South Korea
$3.43M +$286K +15,794 +8%
Millennium Management
30
Millennium Management
New York
$3.32M -$47.5K -2,621 -1%
Bank of America
31
Bank of America
North Carolina
$2.61M +$438K +24,151 +18%
RA
32
Royce & Associates
New York
$2.46M -$294K -16,250 -10%
Macquarie Group
33
Macquarie Group
Australia
$2.45M
Rafferty Asset Management
34
Rafferty Asset Management
New York
$2.17M -$455K -25,135 -16%
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
$1.89M +$544K +30,000 +35%
RJFSA
36
Raymond James Financial Services Advisors
Florida
$1.89M +$907K +50,056 +77%
Legal & General Group
37
Legal & General Group
United Kingdom
$1.81M +$24K +1,325 +1%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$1.76M +$27.4K +1,512 +1%
N
39
Nuveen
North Carolina
$1.68M -$24.7K -1,364 -1%
Citigroup
40
Citigroup
New York
$1.67M +$362K +19,949 +24%
RJA
41
Raymond James & Associates
Florida
$1.66M +$1.46M +80,706 +405%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.42M +$99.7K +5,500 +7%
TI
43
Trexquant Investment
Connecticut
$1.41M +$1.32M +72,742 +552%
Barclays
44
Barclays
United Kingdom
$1.35M -$153K -8,468 -9%
JAM
45
Jupiter Asset Management
United Kingdom
$1.22M
CSS
46
Cubist Systematic Strategies
Connecticut
$1.17M -$473K -26,074 -27%
UBS Group
47
UBS Group
Switzerland
$1.1M +$83.3K +4,598 +7%
Stifel Financial
48
Stifel Financial
Missouri
$1.08M +$106K +5,824 +10%
AllianceBernstein
49
AllianceBernstein
Tennessee
$999K
HWAM
50
Hennion & Walsh Asset Management
New Jersey
$994K -$98.3K -5,425 -8%

RGNX Hedge Fund Activity: Q3 2023 in Review

159 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2023, worth a combined $610M — down 18% from $742M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of RGNX and 17 opened new positions — a net loss of 8 holders — while 51 trimmed existing stakes and 62 added.

The largest buyer was Redmile Group, adding an estimated $9.92M. The largest seller was State Street, cutting an estimated $4.69M.

  • 159 institutional investors held Regenxbio (RGNX) as of Q3 2023, down from 167 in Q2 2023.
  • Funds reported $610M of Regenxbio stock for Q3 2023, down 18% quarter-over-quarter.
  • 17 funds opened new Regenxbio positions in Q3 2023 and 25 closed out, a net change of -8 holders.
  • The largest Regenxbio buyer in Q3 2023 was Redmile Group, an estimated $9.92M added.
  • The largest Regenxbio seller in Q3 2023 was State Street, an estimated $4.69M sold.

Based on aggregated 13F filings for Q3 2023.